TaiMed Biologics Valuation
| 4147 Stock | TWD 83.90 1.10 1.29% |
At this time, the company appears to be overvalued. TaiMed Biologics has a current Real Value of NT$72.69 per share. The regular price of the company is NT$83.9. Our model measures the value of TaiMed Biologics from inspecting the company fundamentals such as Shares Outstanding of 252.37 M, return on equity of -0.18, and Operating Margin of (1.47) % as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that TaiMed Biologics' price fluctuation is very steady at this time. Calculation of the real value of TaiMed Biologics is based on 3 months time horizon. Increasing TaiMed Biologics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the TaiMed stock is determined by what a typical buyer is willing to pay for full or partial control of TaiMed Biologics. Since TaiMed Biologics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of TaiMed Stock. However, TaiMed Biologics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 83.9 | Real 72.69 | Hype 83.9 | Naive 82.84 |
The intrinsic value of TaiMed Biologics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence TaiMed Biologics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of TaiMed Biologics helps investors to forecast how TaiMed stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of TaiMed Biologics more accurately as focusing exclusively on TaiMed Biologics' fundamentals will not take into account other important factors: TaiMed Biologics Total Value Analysis
TaiMed Biologics is presently anticipated to have takeover price of 17.73 B with market capitalization of 17.62 B, debt of 536 M, and cash on hands of 1.02 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the TaiMed Biologics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
17.73 B | 17.62 B | 536 M | 1.02 B |
TaiMed Biologics Investor Information
About 17.0% of the company shares are owned by insiders or employees . The company recorded a loss per share of 2.36. TaiMed Biologics had not issued any dividends in recent years. Based on the key indicators related to TaiMed Biologics' liquidity, profitability, solvency, and operating efficiency, TaiMed Biologics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.TaiMed Biologics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. TaiMed Biologics has an asset utilization ratio of 8.97 percent. This indicates that the Company is making NT$0.0897 for each dollar of assets. An increasing asset utilization means that TaiMed Biologics is more efficient with each dollar of assets it utilizes for everyday operations.TaiMed Biologics Ownership Allocation
TaiMed Biologics shows a total of 252.37 Million outstanding shares. TaiMed Biologics has 17.27 % of its outstanding shares held by insiders and 21.66 % owned by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.TaiMed Biologics Profitability Analysis
The company reported the revenue of 413.44 M. Net Loss for the year was (470.93 M) with profit before overhead, payroll, taxes, and interest of 177.82 M.About TaiMed Biologics Valuation
Our relative valuation model uses a comparative analysis of TaiMed Biologics. We calculate exposure to TaiMed Biologics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of TaiMed Biologics's related companies.TaiMed Biologics Inc., a biotechnology company, develops health-care products. The company was founded in 2007 and is based in Taipei City, Taiwan. TAIMED BIOLOGICS operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange.
8 Steps to conduct TaiMed Biologics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates TaiMed Biologics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct TaiMed Biologics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain TaiMed Biologics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine TaiMed Biologics' revenue streams: Identify TaiMed Biologics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research TaiMed Biologics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish TaiMed Biologics' growth potential: Evaluate TaiMed Biologics' management, business model, and growth potential.
- Determine TaiMed Biologics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate TaiMed Biologics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for TaiMed Stock Analysis
When running TaiMed Biologics' price analysis, check to measure TaiMed Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TaiMed Biologics is operating at the current time. Most of TaiMed Biologics' value examination focuses on studying past and present price action to predict the probability of TaiMed Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TaiMed Biologics' price. Additionally, you may evaluate how the addition of TaiMed Biologics to your portfolios can decrease your overall portfolio volatility.